Vertex Pharmaceuticals
VRTX
716 hedge funds and large institutions have $45.2B invested in Vertex Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 74 funds opening new positions, 279 increasing their positions, 244 reducing their positions, and 85 closing their positions.
15% more funds holding in top 10
Funds holding in top 10: 13 → 15 (+2)
14% more repeat investments, than reductions
Existing positions increased: 279 | Existing positions reduced: 244
12% more call options, than puts
Call options by funds: $309M | Put options by funds: $277M
0.08% more ownership
Funds ownership: 96.21% → 96.3% (+0.08%)
0% less capital invested
Capital invested by funds: $45.2B → $45.2B (-$71.4M)
3% less funds holding
Funds holding: 737 → 716 (-21)
13% less first-time investments, than exits
New positions opened: 74 | Existing positions closed: 85
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$401M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$311M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$242M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$228M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$93.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$428M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$220M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$99.7M |
| 4 |
Jennison Associates
New York
|
-$79.7M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$78.2M |
VRTX Hedge Fund Activity: Q2 2019 in Review
716 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q2 2019, worth a combined $45.2B — down 0.16% from $45.2B a quarter earlier.
Sellers outnumbered buyers: 85 funds closed out of VRTX and 74 opened new positions — a net loss of 11 holders — while 244 trimmed existing stakes and 279 added.
The largest buyer was Nuveen, adding an estimated $401M. The largest seller was JP Morgan Chase, cutting an estimated $428M.
- 716 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q2 2019, down from 737 in Q1 2019.
- Funds reported $45.2B of Vertex Pharmaceuticals stock for Q2 2019, down 0.16% quarter-over-quarter.
- 74 funds opened new Vertex Pharmaceuticals positions in Q2 2019 and 85 closed out, a net change of -11 holders.
- The largest Vertex Pharmaceuticals buyer in Q2 2019 was Nuveen, an estimated $401M added.
- The largest Vertex Pharmaceuticals seller in Q2 2019 was JP Morgan Chase, an estimated $428M sold.
Based on aggregated 13F filings for Q2 2019.